Puma Biotechnology Inc (NYSE:PBYI) Position Increased by Geode Capital Management LLC

Geode Capital Management LLC boosted its stake in shares of Puma Biotechnology Inc (NYSE:PBYI) by 17.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 232,371 shares of the biopharmaceutical company’s stock after buying an additional 34,190 shares during the period. Geode Capital Management LLC owned about 0.63% of Puma Biotechnology worth $8,644,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in PBYI. Legal & General Group Plc boosted its position in shares of Puma Biotechnology by 2.8% in the first quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 249 shares during the last quarter. Franklin Street Advisors Inc. NC boosted its stake in Puma Biotechnology by 3.4% in the first quarter. Franklin Street Advisors Inc. NC now owns 30,000 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 1,000 shares during the last quarter. Swiss National Bank boosted its stake in Puma Biotechnology by 2.1% in the first quarter. Swiss National Bank now owns 54,730 shares of the biopharmaceutical company’s stock valued at $2,036,000 after buying an additional 1,100 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Puma Biotechnology by 10.0% in the first quarter. Wells Fargo & Company MN now owns 24,151 shares of the biopharmaceutical company’s stock valued at $899,000 after buying an additional 2,201 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Puma Biotechnology by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,142 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 2,247 shares during the last quarter. 80.98% of the stock is owned by institutional investors.

Puma Biotechnology Inc (NYSE PBYI) traded down 1.18% during mid-day trading on Friday, reaching $79.75. The company’s stock had a trading volume of 744,991 shares. The firm’s market capitalization is $2.97 billion. Puma Biotechnology Inc has a 52 week low of $28.35 and a 52 week high of $98.85. The firm’s 50 day moving average price is $87.66 and its 200 day moving average price is $58.07.

Puma Biotechnology (NYSE:PBYI) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by $0.78. On average, analysts anticipate that Puma Biotechnology Inc will post ($8.62) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology Inc (NYSE:PBYI) Position Increased by Geode Capital Management LLC” was first posted by BNB Daily and is owned by of BNB Daily. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/geode-capital-management-llc-raises-stake-in-puma-biotechnology-inc-nysepbyi-updated-updated.html.

A number of equities research analysts have weighed in on PBYI shares. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $89.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, May 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $110.00 price objective (down previously from $118.00) on shares of Puma Biotechnology in a research note on Thursday, August 10th. Zacks Investment Research cut Puma Biotechnology from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Cowen and Company reiterated a “market perform” rating on shares of Puma Biotechnology in a research note on Monday, May 22nd. Finally, BidaskClub lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. Puma Biotechnology presently has a consensus rating of “Buy” and an average target price of $109.56.

In other news, insider Alan H. Auerbach sold 13,175 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the transaction, the insider now directly owns 4,170,623 shares of the company’s stock, valued at $395,083,116.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Adage Capital Partners Gp, L.L sold 507,128 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $87.84, for a total transaction of $44,546,123.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,010,261 shares of company stock worth $159,425,452. Insiders own 22.70% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply